1. Introduction {#s0005}
===============

Malignant airway obstruction (MAO) is a serious situation in 20--30% cases of lung cancer, resulting in dyspnea, decreased functional status, and asphyxiation risk \[[@bb0005]\]. In addition, metastases to the lungs from other malignancies, including esophageal, thyroid, breast, colon, and renal cell cancers, commonly result in MAO \[[@bb0010], [@bb0015]\]. While occasionally surgery may be an option for the long-term management of MAO, most cases are considered inoperable due to the late-stage diagnosis, poor tolerance, and high incidence of perioperative mortality \[[@bb0020]\]. For patients with inoperable MAO, various treatment modalities, including laser therapy, contact electrocautery, argon plasma coagulation, cryotherapy, photodynamic therapy, brachytherapy, etc., are employed to recanalize the obstruction \[[@bb0015], [@bb0025]\].

Covered or uncovered stent placement has been regarded as a safe and effective technique for the immediate palliation of dyspnea \[[@bb0030]\]. However, stent restenosis occurs in 5--45% of cases as a result of neoplastic infiltration through the meshes into the lumen and tumor overgrowth at the ends of the stent \[[@bb0035], [@bb0040], [@bb0045]\]. Conventional external beam radiotherapy (EBRT) after airway stenting provides an option for such restenosis with borderline survival benefits \[[@bb0050], [@bb0055]\]. Unfortunately, 37% of patients failed to complete radiation therapy because of intolerable complications, and more than one-third of patients succumbed to tumor growth-related asphyxia \[[@bb0050]\]. Based on the successful clinical application of a radioactive stent in patients with esophageal carcinoma or malignant biliary obstruction \[[@bb0060], [@bb0065], [@bb0070]\], the tracheal stent loaded with ^125^I seeds was developed for preventing restenosis of the stent. The feasibility and safety of inserting such a radioactive stent into the airway have been demonstrated in the healthy beagle dog models \[[@bb0075]\]. In this prospective study, we aim to evaluate the safety and efficacy of this radioactive bare metal stent (RBMS) versus conventional bare metal stent (CBMS) in patients with inoperable MAO.

2. Materials & Methods {#s0010}
======================

2.1. Study Design and Participants {#s0015}
----------------------------------

This single-center, randomized, controlled study was approved by the Institutional Review Board of our hospital. Informed consent was obtained from all patients and their families. The inclusion criteria and exclusion criteria are listed in [Table 1](#t0005){ref-type="table"}.Table 1Inclusion and exclusion criteria.Table 1Inclusion criteria1)Between 18 and 75 years of age2)Pathology-confirmed extrinsic compression or mixed pattern MAO resulting from cancer3)Airway obstruction at trachea and/or left/right bronchus4)Dyspnea of Hough-Jones grade III-IV \[[@bb0035]\]5)Inoperable lesions assessed by two experienced surgeons or patients\' refusal of surgical treatment6)Willingness and ability to comply with the study proceduresExclusion criteria1)Suspected benign airway obstruction2)Intrinsic obstruction3)Perforation of any bronchus within the tracheal tree4)A history of metallic tracheal stent placement, EBRT, or airway surgery

The patients were randomly allocated, with a 1:1 ratio, into the RBMS or CBMS group. The randomization sequence was computer-generated using a block randomization method (given a block size of four). The coded treatment assignments were stored at a special coordinating center in sealed, consecutively numbered, opaque envelopes, which would be unsealed by contacting the coordinating center until the participant enrollment. With the radiologists being the only exception, all patients, research nurses, and statisticians performing the analyses in this study were masked to the results of randomization.

2.2. Sample Size {#s0020}
----------------

Based on the median survival time of 90--181 days after treatment with CBMS placement in the previous studies \[[@bb0035], [@bb0040], [@bb0080]\], we hypothesized that the median survival time of the patients in the CBMS group would be approximately 3 months. While the median survival time of EBRT combined with stent placement was approximately 5--8 months \[[@bb0050], [@bb0085], [@bb0090]\], we hypothesized that the expected median survival in the RBMS group would be approximately 7 months according to our previous experience. With an alpha level of 0·05 (one-sided test), the smallest calculated sample size was 24 patients per group. When the censored cases were considered, 33 patients per group would be necessary to detect significant differences.

Fibro-bronchoscopy was performed in all patients 3 days after stent insertion to evaluate the status of the expansion and position of the stent. The telephone follow-ups were performed by a research nurse on a monthly basis, and the patients were asked to return for laboratory and imaging examinations every month or whenever dyspnea recurred. Each visit included the evaluation of symptoms and signs related to airway obstruction, laboratory values (white blood cell count and immunoglobulin), and a computed tomography (CT) scan. A single-photon emission computed tomography (SPECT) scan was performed in patients with RBMS in the first and third months after stent placement.

2.3. Endpoints and Definitions {#s0025}
------------------------------

The primary endpoint was stenosis grade, and the secondary endpoints included technical success, overall survival (OS), and complications and side effects related to stent placement. Stenosis grade was classified as 5 grades on the cross-sectional CT imaging area: grade 0 = non-appreciable stenosis; grade 1, 2, 3, and 4 = 25, 50, 75, and 90% decrease in area, respectively; grade 5 = complete obstruction \[[@bb0095]\]. *Re*-stenting was performed if the grade of restenosis was higher than 3. Technical success was defined as successful placement of the stent across the stricture with appropriate positioning of the stent and full expansion. OS was defined as the time from stent placement to death or the last follow-up. Complications or side effects were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE, version 4·02). Possible radiation related complications included neutropenia, decrease in IgA, IgG, and IgM, and leakage of radioactive seeds. Neutropenia was defined as a total white blood cell count \<4000/mm^3^ in the plasma. The leakage of radioactive seeds was defined as the detection of non-target radioactive source verified by radiography and/or SPECT.

2.4. Procedure {#s0030}
--------------

Before the procedure, blood biochemistry, performance status, clinical signs, and imaging were evaluated in all patients. Pre-procedure fibro-bronchoscopy was performed to assess the stenosis of the airway in patients with stable vital signs. Both RBMS and CBMS were provided by MTN Nanjing MicroInvasive Medical (Nanjing, China). The stent was "L", "I", or "Y" shaped with the following dimensions: the tracheal part with 18 mm in diameter and 50 mm in length, the right bronchial limb with 14 mm in diameter and 20 mm in length, and the left bronchial limb with 12 mm in diameter and 30 mm in length. The sheaths (6·0 mm in length × 1·3 mm in diameter) containing ^125^I radioactive seeds were attached to the outer surface of the stent. (Shanghai Xinke Medical Company Co., Ltd., Shanghai, China; [Fig. 1](#f0005){ref-type="fig"}). The ^125^I seed has a half-life of 59·4 days with an effective irradiating distance of 17 mm. The principal photon emissions are 27·4--31·5 keV X-ray and 35·5 keV γ-ray. ^125^I seeds with an activity of 0·8 mCi were administered to the RBMS group. The number, distribution, and dose of the seeds were determined according to the dedicated treatment planning system (TPS, Qilin Co., Ltd., Peking, China).Fig. 1Photograph of a radioactive bare metallic stent loaded with ^125^I seeds.Fig. 1

The procedures of RBMS placement were performed by experienced interventional radiologists (J.H.G., G.J.T., and G.Y.Z., with, 27, 30, and 19 years of experience in interventional radiology, respectively) under fluoroscopic guidance in a C-arm angiographic unit (Innova 3100; GE Healthcare, Waukesha, WI). Under general anesthesia, the stent catheter coaxial with a 0·035-in. guidewire (Boston Scientific Corporation, Natick, MA) was orally placed over the stricture of lesion through the tracheal cannula, and then the stent loaded with radioactive seeds was delivered. After the stent was released in the target position under the guidance of radiopaque marker of the stent, the stent delivery catheter was immediately withdrawn. The placement of CBMS was conducted in the same manner except for the preloading of ^125^I seeds into the sheaths.

After stent placement, aerosol inhalation of budesonide (4000 iu, SPH No.1 Biochemical & Pharmaceutical Co., Ltd., Shanghai, China), dexamethasone (10 mg, Aodong Medicine Industry Group Co., Ltd., Shanghai, China), and ipratropine (500 μg, SCS Boehringer Ingelheim Comm. V, Brussels, Belgium) were intermittently administered in all patients within the first week.

All managements related to the safety of RBMS met the criteria recommended by the International Commission on Radiological Protection \[[@bb0100]\] and were reviewed by an independent radiation safety supervision group. The radiologists who performed the procedures were required to wear lead bib, lead gloves, lead glasses, and lead aprons. The patients with RBMS were kept in a single room for 7 days before discharge, and the accompanying family members were asked to stay at least one meter away from the patient.

2.5. Statistical Analysis {#s0035}
-------------------------

All the 66 patients at randomization were included into the Intention to treat analysis in this study. Categorical variables are described as frequencies and percentages. Continuous data were expressed as mean ± standard deviation (SD) or median \[95% confidence interval (CI)\]. Sex, tumor type, Eastern Cooperative Oncology Group (ECOG) performance status score, location of disease, stenosis grade, and dyspnea score were analyzed using the Chi-square test. The age and laboratory values prior to the stent treatment were analyzed using independent samples *t-*test. The laboratory results and ECOG scores pre- and post-procedure in the same group were compared using the Wilcoxon signed-rank test, while the difference pre- and post-procedure between the two groups were compared using the Mann-Whitney test. The stent placement related side effects and complications between the two groups were analyzed using the Fisher exact-test. The cubic spline function was used for comparing the stenosis grade after stent placement. The Kaplan-Meier method and log-rank test were used for the evaluation of survival time. A *p* value of \<0·05 indicates a significant difference. The statistical analysis was performed using a computer software (SPSS, version 19·0, IBM Corp, Armonk, New York).

3. Results {#s0040}
==========

3.1. Patients and Procedures {#s0045}
----------------------------

Between September 2013 and July 2015, 66 patients with inoperable histologically- diagnosed MAO with dyspnea were equally and randomly assigned to the RBMS or CBMS group. The initial stent placement procedure was successful in all 66 patients. Seven patients lost to follow-up (4 in the RBMS group versus 3 in the CBMS group; [Fig. 2](#f0010){ref-type="fig"}). The baseline characteristics of all patients were listed in [Table 2](#t0010){ref-type="table"}. There was no significant difference in any item between the two groups.Fig. 2Flow diagram.Fig. 2Table 2Baseline demographic and disease characteristics of randomized patients.Table 2CharacteristicsCBMS group (*n* = 33)RBMS group (*n* = 33)*P* valueAge (yr)[a](#tf0005){ref-type="table-fn"}62·06 ± 6·9861·58 ± 6·400·770Sex0·415 Male2522 Female811Tumor type0·789 Lung cancer2422 Esophageal cancer911ECOG0·523 279 32021 463Location(s) of disease0·422 M or R or L1311 M + R or M + L118 M + L + R914Length of stenosis28·58 ± 6·7727·61 ± 5·800·261Stenosis grade0·671 234 32015 468 546Dyspnea score0·513 21917 3711 475Distant metastasis0·375 Yes57 No2826Laboratory values[a](#tf0005){ref-type="table-fn"}White blood cell (×10^9^/L)8·12 ± 4·338·80 ± 3·950·356 Immunoglobulin A2·79 ± 1·162·67 ± 1·040·657 Immunoglobulin G11·81 ± 3·7411·50 ± 3·260·847 Immunoglobulin M1·49 ± 0·701·52 ± 0·690·985[^2][^3][^4][^5]

The matched peripheral dose (MPD) at the reference point (10 mm from the seed surface) was approximately 35--45 Gy, calculated using a computerized TPS. The scores of ECOG performance status decreased significantly in both groups 3 days after stenting, with no difference detected between two groups ([Table 3](#t0015){ref-type="table"}). There were no significant changes in the white blood cell counts or immunological tests (IgA, IgG, and IgM) before and after stent placement in either group or in the variance between the two groups ([Table 3](#t0015){ref-type="table"}). Atelectasis was completely resolved in 5 patients (83·33%) and partially resolved in 1 patient (16·67%) in the RBMS group, as compared to 6 patients (85·71%) and 1 patient (14·29%) in the CBMS group, respectively.Table 3Various values of pre- and post-stent placement.Table 3CharacteristicsCBMS group (n = 33)RBMS group (n = 33)*P* valueWhite blood cell (×10^9^/L)0·920[a](#tf0010){ref-type="table-fn"} Before8·80 ± 3·958·12 ± 4·32 After9·22 ± 3·718·45 ± 4·37 *P* value0·188[b](#tf0015){ref-type="table-fn"}0·191[b](#tf0015){ref-type="table-fn"}Immunoglobulin A0·660[a](#tf0010){ref-type="table-fn"} Before2·66 ± 1·042·79 ± 1·16 After2·67 ± 0·892·83 ± 1·12 *P* value0·746[b](#tf0015){ref-type="table-fn"}0·926[b](#tf0015){ref-type="table-fn"}Immunoglobulin G0·668[a](#tf0010){ref-type="table-fn"} Before11·51 ± 3·2611·81 ± 3·74 After12·25 ± 3·5012·01 ± 3·19 *P* value0·382[b](#tf0015){ref-type="table-fn"}0·723[b](#tf0015){ref-type="table-fn"}Immunoglobulin M0·501[a](#tf0010){ref-type="table-fn"} Before1·52 ± 0·691·49 ± 0·70 After1·60 ± 0·721·55 ± 0·64 *P* value0·160[b](#tf0015){ref-type="table-fn"}0·386[b](#tf0015){ref-type="table-fn"}ECOG Before2·97 ± 0·642·82 ± 0·580·912[a](#tf0010){ref-type="table-fn"} After2·55 ± 0·942·39 ± 1·00 *P* value0·004[b](#tf0015){ref-type="table-fn"}0·010[b](#tf0015){ref-type="table-fn"}[^6][^7][^8][^9]

3.2. Primary Endpoint {#s0050}
---------------------

The baseline stenosis of all patients in both groups was immediately relived following the stent placement and then increased gradually as per each follow-up. Follow-up fibro-bronchoscopy 3 days after stent placement showed that all stents expanded fully without stent migration. The mean stenosis grade of the RBMS group was 0·94 three days after stent placement versus 3·48 before the procedure, and that of the CBMS group was 0·97 versus 3·33. No significant differences between two groups were observed on the third day after stent placement (*p* = 0·558). One month after stent placement, the stenosis grades increased in both groups with non-significant difference (p = 0·073). Since the second month to the last follow-up, the difference in stenosis score between two groups turned out to be significant at each visit (p~2--5~ *\<* 0·001, p~6~ = 0·006*,* p~7~ = 0·036; [Fig. 3](#f0015){ref-type="fig"}).Fig. 3Stenosis grades after stent insertion.Graphs show mean stenosis grade 95% CI. Higher scores represent increased stenosis.Fig. 3

Stent restenosis was observed in 21·2% (7/33) of patients in the RBMS group and 45·45% (15/33) in the CBMS group (p = 0·037). Two additional conventional bare stents (one stent per patient) were placed over the initial stents when restenosis occurred in two patients with RBMS (one on Day 172 and the other one on Day 203 after stent placement). While 6 stents (one stent per patient) were placed in the CBMS group due to restenosis at a median time of 149 days (range, 113--182 days) after stent placement. *Re*-intervention was not attempted in 14 patients (5 in the RBMS group and 9 in the CBMS group) because of poor systemic conditions (*n* = 6), expected short life-span (*n* = 2), patients\' refusal (*n* = 4), or other reasons (n = 2) although restenosis was demonstrated.

3.3. Secondary Endpoints {#s0055}
------------------------

The technical success rate of stent placement was 100% in both groups. After general anesthesia, median procedure times (from initial insertion to complete withdrawal of stent catheter) were 30 and 28 s in the RBMS and CBMS groups, respectively (*p* = 0·471). Post-procedure SPECT examination in the RBMS group did not show radioactive concentration outside the target position of the airway. Absorbed dose of radiation monitoring during the operation was approximately 12,892--19,155 mGycm^2^. None of the ^125^I seeds was lost from the stent during the delivery or deployment process.

Fifty (25 per group) of the 59 patients died in a median follow-up period of 154 days (range, 15--335 days). The 30-day mortality was 3·33% (1/33) in the RBMS group versus 3·33% (1/33) in the CBMS group (*p* = 0·999). The median OS time in the RBMS group was 170 days (95% CI: 146, 194), significantly longer than 123 days (95% CI: 94, 152) in the CBMS group (*p* = 0·015; [Fig. 4](#f0020){ref-type="fig"}). There was no difference in terms of causes of death, with hemoptysis in 2 and 3 patients, pulmonary infection in 3 and 3 patients, and cachexia or multiple organ failure in 20 and 19 patients, respectively, in the RBMS and CBMS group ([Fig. 5](#f0025){ref-type="fig"}).Fig. 4Kaplan-Meier overall survival curve.The median overall survival was 170 days (95% CI: 146, 194) in the RBMS group and 123 days (95% CI: 94, 152) in the CBMS group (*p* = 0·015).Fig. 4Fig. 5An esophageal cancer patient complicated by mediastinal lymph node metastasis, atelectasis, and pleural effusion.5A: CT scan showed that the left bronchus had been involved and completely obstructed (black arrow). 5B: Follow-up CT one month post operation showed the left lung re-expanded, and pleural effusion was absorbed completely.Fig. 5

The rate of overall complications was 69·70% in the RBMS group versus 66·67% in the CBMS group (p = 0·999). The overall incidence of grade 3 or 4 complications was also comparable (24.24% v 27.27%; p = 0·999). Chest pain, fistula formation, pulmonary infection, and hemoptysis were observed in 8, 1, 4, and 9 patients in the RBMS group, respectively, whereas 9, 2, 5, and 7 were detected in the CBMS group, respectively (*p* \> 0·05) ([Table 4](#t0020){ref-type="table"}).Table 4Complications after stent placement.Table 4ComplicationsCBMS group (n = 33)RBMS group (n = 33)*P* valueAll eventsCTCAE GradeAll eventsCTCAE Grade12≥312≥3Chest pain963086200·999Fistula formation201110010·999Pneumonia501440130·999Stent migration00000000n.d.Hemoptysis713392250·775Total23788228590·999[^10][^11][^12][^13]

4. Discussion {#s0060}
=============

MAO usually results from late-stage malignancies such as lung cancer, esophageal carcinoma, and malignant lymph nodules. The long-term survival of patients with MAO is dismal. Systemic chemotherapy is a standard therapy for late-stage lung cancer and esophageal carcinoma, but this treatment is hardly tolerable to some patients with poor performance status and does not achieve immediate recanalization of the air passage \[[@bb0105]\]. Although EBRT has been recommended as a preferred choice for the palliative treatment of inoperable MAO, the effects are often delayed and unpredictable. Moreover, EBRT may aggravate airway obstruction related to early tumor edema \[[@bb0050]\]. Optionally, the expandable metallic stent placement served as a palliative therapy with the advantage of rapid relief of MAO \[[@bb0030]\]. Unfortunately, stent restenosis has a high rate up to 24% within 3 months due to the ingrowth of the initial malignancies \[[@bb0035]\]. Moreover, placement with a conventional SEMS offers limited survival benefits in the absence of locoregional therapy for endobronchial lesions. Recently, a novel stent loaded with ^125^I seeds was developed and exhibited promising outcomes in treating esophageal cancer, malignant biliary tract obstruction, and portal vein tumor thrombosis caused by hepatocellular carcinoma \[[@bb0060], [@bb0065], [@bb0070], [@bb0110], [@bb0115]\]. Theoretically, this new radioactive stent may offer the advantages of both rapidly achieving lumen patency and enabling continuous brachytherapy to control the malignancies. To our best knowledge, this is the first attempt of the combination of ^125^I seeds brachytherapy and stent placement in treating inoperable MAO.

Brachytherapy can be delivered as low-dose-rate (LDR) therapies, in which \<1 Gy per hour is delivered by radioactive sources that are left permanently in place, or as high-dose-rate (HDR) therapies, in which the radiation is delivered over several courses \[[@bb0120]\]. Iridium-192 (^192^Ir) is the most common isotope used for HDR brachytherapy for airway malignancies in the previous reports, with common dose fractionation regimens ranging from 4 treatments of 5 Gy each to 2 treatments of 15 Gy each \[[@bb0125]\]. However, ^125^I seeds were employed as the brachytherapy source loaded on the airway stent in this study, with the administrated dose of 35--45 Gy. ^125^I seeds may provide advances such as continuous LDR brachytherapy and a buildup of radiation damage by synchronizing tumor cells to radiosensitive G2-M phase \[[@bb0130]\]. Besides, as a LDR source, it is understandable that ^125^I allows efficient repair of sublethal radiation damage in normal tissue \[[@bb0135]\]. In addition, the easy preparation and relatively low energy (27·4--31·5 keV) of the emitted X-rays ensured reduced normal tissue exposure and safety for radiologists during the radioactive stent preparation and implantation. In the present study, the technical success rate of the RBMS groups achieved 100% during a short operation time*.* Neither ^125^I seed loss nor stent migration occurred during the delivery. All radioactive stents were fully expanded within 3 days after placement. The absorbed dose during the operation was relatively low and easily accepted. These results may be owing to the reasonable choice of isotope, sophisticated design of assembling, and easy controlled delivery system by an experienced interventional radiologist.

In the previous studies on esophageal cancer using the radioactive stent, the results showed that the radioactive stent allows a longer relief of dysphagia compared to the conventional stent in both a single and multiple institutional randomized controlled studies \[[@bb0060], [@bb0070]\]. Furthermore, the novel stent loaded with ^125^I seeds dedicated to biliary tract was developed and showed longer patency in both the single and multicenter institutional randomized controlled studies compared to a conventional stent in malignant biliary obstruction \[[@bb0065], [@bb0115]\]. In the present study, although the mean stenosis grade decreased in both groups immediately after stent placement, the stenosis grades increased gradually in both groups mainly due to the tumor infiltration and low-dose rate nature of ^125^I seed. Meanwhile, from the second month to the last follow-up, the difference in stenosis score between two groups turned out to be significant at each visit. This phenomenon may be attributed to the continuous increase of accumulated dose of ^125^I seeds in the RBMS group. These results reached the design goal of reducing restenosis of the stent by inhibiting tumor growth with ^125^I seeds brachytherapy.

Although the previous trials show longer survival with the radioactive stent in esophageal cancer and malignant biliary obstruction \[[@bb0060], [@bb0065], [@bb0070], [@bb0115]\], it is uncertain whether it can prolong the OS in MAO caused by various malignancies. Conventional EBRT following stent insertion was previously reported in patients with inoperable MAO, with a modest median OS of 3·44 months (95% CI: 1·1, 5·8) \[[@bb0050]\]. As an alternative choice, endobronchial HDR brachytherapy with ^192^Ir was delivered to treat inoperable MAO with considerable symptom alleviation, good tumor control, and improved OS \[[@bb0125]\]. In this study, the OS in the RBMS group was significantly longer than that in the CBMS group and also seemed longer than that previously reported using CBMS or HDR brachytherapy in the literature \[[@bb0015], [@bb0140], [@bb0145], [@bb0150]\]. The survival benefit may be attributed to the inhibition of tumor growth by the brachytherapy.

Previous studies indicated that the decrease in white blood cell counts and total immunoglobulins (IgA, IgG, and IgM) may be related to the long-term LDR radiation \[[@bb0155]\]. In this study, Neither white blood cell counts nor IgA, IgG, and IgM levels showed significant changes between pre- and post-procedures. This finding appeared to be associated with diverse types of tissue reaction which may result from different dosimetric properties with various isotopes and irradiation techniques \[[@bb0160]\]. SPECT examination following the stent placement disproved any ^125^I seed leakage outside the location of the stent, which indicates a well-formed mechanical design of the radioactive stent. Airway infection after stenting varies from 5·9% to 10% in the previous literature \[[@bb0040], [@bb0090], [@bb0165]\]. The various data reflect the undefined diagnostic criteria because of the pre-existed respiratory infection before stent placement in many MAO patients. In the present study, there was no difference in the occurrence of respiratory tract infection between the RBMS and CBMS groups, indicating that the radioactive stent does not increase the risk of infection. The incidences of grade ≥ 3 and total complications between the two groups were comparable in this study, suggesting that the combination of brachytherapy and stenting did not increase the incidence of treatment-related complications.

This study has several limitations. Firstly, due to the various experience of the interventional radiologists who performed the procedures and various morphological characteristics of the malignancies, the precise localization of the radioactive seeds as programmed by the preoperative plan of the TPS is sometimes challenging. Secondly, the tumor response was not assessed using any radiological measurement (e.g. RECIST criteria) for the stenting caused compression of the tumor. Thirdly, a personalized protocol on radiation dose prescription was not adopted, although the etiologies of MAO varied from patient to patient in the present study. Fortunately, the dose used in this study seems to be satisfactory in compromising treatment effects and tolerance. Nevertheless, it is warranted to have studies focusing on the radiation dose of ^125^I seeds in MAO.

In conclusion, the placement of RBMS in patients with inoperable MAO is feasible and safe. It significantly reduces the incidence of restenosis and improves the overall survival compared with CBMS.
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